Vials vs pens for retatrutide: pros and cons
South African sellers offer retatrutide in two main formats. One is a sealed vial of freeze-dried (lyophilised) powder. The other is a pre-filled pen that holds the peptide already in solution. This article compares the two as products: how stable they are, how they travel, whether they can be checked by a lab, and what they cost.
It is not a guide to use. We do not cover dosing, preparation or administration.
Stability: powder vs solution
Water drives most chemical breakdown of peptides and proteins. For that reason, drug makers often turn proteins into a dry solid to get an acceptable shelf life. A long-cited review in the International Journal of Pharmaceutics says exactly this, and names freeze-drying as the most common method (Wang, 2000).
The same review adds two caveats. Freeze-drying itself stresses the molecule. And a dry product can still have limited long-term stability. So "powder" does not mean "stable forever". It depends on how well it was made.
A vial's advantage also applies only while the powder is dry. Once dissolved, it is a solution too.
Liquid products can also be stable when they are properly formulated. Approved GLP-1 pens are liquid. Their maker says they are kept refrigerated until the expiry date and can be kept for up to 56 days after first use (Novo Nordisk). That shows a well-made liquid pen can work. Whether a grey-market retatrutide pen is well made is unknown. Its formula and real shelf life are not published.
Temperature and light
The ICH guideline on photostability requires makers to test whether light exposure causes unacceptable change (ICH Q1B). We found no published heat or light data for any retatrutide product sold in South Africa, in either format.
Delivery matters here. In our re-checks, few sellers described any cold chain. One pen listing included a cold pack; at least one vial seller stated no cold chain. As a general rule, a dry product should tolerate a warm courier trip better than a solution. We could not confirm this for retatrutide specifically.
Can you verify what is inside?
In theory, a lab report (COA) can be tied to a vial batch. In practice, this rarely happens in South Africa.
On 2026-09-25, only 3 of the 17 sellers we rate published any retatrutide lab report. All three were for vials. None could be tied to stock on sale that day: two reports list the batch as "Unknown", and the third seller no longer lists retatrutide. No seller published a report for a pen. See how we rate for how we check this.
Pens are not untestable. Some sellers outside South Africa publish third-party purity results for pens, with batch codes (example testing page). The independent tester Finnrick lists 200 retatrutide tests, but does not split results by format. So we cannot say, from public data, that pens fail tests more often than vials.
What we can say: no retatrutide pen sold here comes from a licensed maker, because no retatrutide product is approved in South Africa. Branded medicine pens have been counterfeited before, including fake needles whose sterility could not be confirmed (FDA). With a pen, both the liquid and the device are unknown.
Contamination
Both formats become multi-use containers once opened. US guidance says an opened multi-dose vial should be discarded within 28 days unless the maker states otherwise, and that preservatives do not give complete protection against contamination (CDC). A pen cartridge is also entered many times. We found no evidence that one format is clearly cleaner than the other in grey-market use.
One point favours pens. A pen is filled before sale. A vial needs a separate liquid added by the buyer, which means more components and more handling outside a factory. Whether pens are actually filled in clean conditions is unknown.
Price per mg
Across 17 South African sellers on 2026-09-25, the median cheapest in-stock price was R50 per mg (see our ratings). We then compared vials and pens sold by the same seller, at similar sizes:
| Seller (brand, size) | Vial R/mg | Pen R/mg | Pen premium |
|---|---|---|---|
| Cronopharm (30 mg vial, 32 mg pen) | 53.33 | 56.25 | +5% |
| Genesis Peptides (Noventra, 32 mg) | 61.25 | 71.56 | +17% |
| Peptera (30 mg) | 56.67 | 70.00 | +24% |
| Lekker Peptides (Noventra, 32 mg) | 53.13 | 60.94 | +15% |
| Health and Fitness ZA (UPA, 30 mg) | 60.00 | 66.67 | +11% |
| Health and Fitness ZA (HD, 32 mg) | 51.56 | 78.13 | +52% |
In all six pairs, the pen cost more per mg, by 5% to 52%. Across the whole market the picture is less clean. Two 64 mg pens (R43.28 and R46.88 per mg) were cheaper than the R50 median and cheaper than many sellers' vials.
Accessories and waste
Vial listings often bundle extras: a bottle of bacteriostatic water, syringes and swabs. Some do not, and the buyer must source them. Pen listings usually include pen needles. A disposable pen is thrown away whole, device and all. Reusable pen devices cost extra: R450 at one seller, and about R500 more than the plain vial at another.
Vials: pros and cons
| Pros | Cons |
|---|---|
| Dry powder is generally more stable in storage than a solution | Advantage ends once the powder is dissolved |
| Likely to tolerate warm transit better (general principle) | Needs extra items, not always included |
| Cheaper per mg than the same seller's pen in all six pairs we found | More handling by the buyer, more room for contamination |
| All published South African retatrutide lab reports are for vials | None of those reports could be tied to current stock |
| Less plastic and device waste | Multi-use once opened, with the same limits as any multi-dose vial |
Pens: pros and cons
| Pros | Cons |
|---|---|
| Arrives ready-made, with fewer separate parts | Peptide is already in solution; formula and shelf life unpublished |
| Filled before sale, so less handling by the buyer | Filling conditions unknown |
| Built-in dose marking is a genuine convenience | 5% to 52% dearer per mg than the same seller's vial |
| Pens can be lab-tested (some sellers abroad do so) | No South African seller published a pen lab report |
| Needles usually included | Device and liquid both come from unlicensed makers; whole pen discarded |
Our conclusion
On the evidence, vials come out ahead on two points. They are cheaper per mg when the same seller offers both. And dry powder is, in general, more stable in storage and transit than a solution.
On other points the case for vials is weaker than often claimed. Their stability advantage ends once dissolved. Their verification advantage is mostly theoretical in South Africa: no seller's retatrutide test could be tied to current stock, in any format. Contamination risk looks similar once either format is in use.
Pens win on convenience and dose marking, and they involve less handling by the buyer.
So vials are the better value and the more robust product in storage. They are not clearly safer or better verified. Whichever format a seller offers, the most useful signal is a current lab report tied to the batch on sale. Almost no one in South Africa provides one yet.
Sources
- Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm. 2000;203:1–60. PubMed 10967427
- Novo Nordisk Medical. GLP-1 RAs storage and stability. novonordiskmedical.com
- ICH Q1B. Stability testing: photostability testing of new drug substances and products. ich.org
- CDC. Preventing unsafe injection practices. cdc.gov
- FDA. FDA warns consumers not to use counterfeit Ozempic found in U.S. drug supply chain. fda.gov
- Finnrick. Retatrutide testing results. finnrick.com
- ProPeptide. Lab test results (pen batches). propeptide6.com
- RetaRadar seller re-checks and scores, snapshot 2026-09-25 (research/stage1/recheck, research/stage2/scores).
Retatrutide is an investigational compound. It is not approved for general medical or consumer use in South Africa. This article is for information only and is not medical advice.